Identification of a Rare 3 bp BRAF Gene Deletion in a Thyroid Nodule by Mutant Enrichment with 3ʹ-Modified Oligonucleotides Polymerase Chain Reaction
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumor, and 36-69% of PTC cases are caused by mutations in the BRAF gene. The substitution of a valine for a glutamic acid (V600E) comprises up to 95-100% of BRAF mutations; therefore, most diagnostic methods, including allele-specific PCR and real-time PCR, are designed to detect this mutation. Nevertheless, other mutations can also comprise the genetic background of PTC. Recently, a novel and sensitive technique called mutant enrichment with 3’-modified oligonucleotides (MEMO) PCR has been introduced. When we applied allele-specific PCR and MEMO-PCR for the detection of the BRAF V600E mutation, we found an unusual 3’ bp deletion mutation(c.1799_1801delTGA) only when using MEMO-PCR. This deletion results in the introduction of a glutamic acid into the B-Raf activation segment (p.V600_K601delinsE), leading to an elevated basal kinase activity of BRAF. This is the first report of a rare 3 bp BRAF deletion in a PTC patient that could not be detected by allele-specific PCR.
Abstract
Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumor, and 36-69% of PTC cases are caused by mutations in the BRAF gene. The substitution of a valine for a glutamic acid (V600E) comprises up to 95-100% of BRAF mutations; therefore, most diagnostic methods, including allele-specific PCR and real-time PCR, are designed to detect this mutation. Nevertheless, other mutations can also comprise the genetic background of PTC. Recently, a novel and sensitive technique called mutant enrichment with 3’-modified oligonucleotides (MEMO) PCR has been introduced. When we applied allele-specific PCR and MEMO-PCR for the detection of the BRAF V600E mutation, we found an unusual 3’ bp deletion mutation(c.1799_1801delTGA) only when using MEMO-PCR. This deletion results in the introduction of a glutamic acid into the B-Raf activation segment (p.V600_K601delinsE), leading to an elevated basal kinase activity of BRAF. This is the first report of a rare 3 bp BRAF deletion in a PTC patient that could not be detected by allele-specific PCR.
참고문헌 (10)
- Kimura ET, "High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET", PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, 2003, pp.63, 1454~1457
- Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
- Cohen Y, "BRAF mutation in papillary thyroid carcinoma", J Natl Cancer Inst, 95, pp.625~627 (2003)
- Fukushima T, "BRAF mutations in papillary carcinomas of the thyroid", Oncogene, 22, pp.6455~6457 (2003)
- Trovisco V, "BRAF mutations are associated with some histological types of papillary thyroid carcinoma", J Pathol, 202, pp.247~251 (2004)
- Lee ST, "Mutant enrichment with 3'-modified oligonucleotides a practical PCR method for detecting trace mutant DNAs", J Mol Diagn, 13, pp.657~668 (2011)
- Lee EJ, "Deletion mutation of BRAF in a serrated adenoma from a patient with familial adenomatous polyposis", APMIS, 115, pp.982~986 (2007)
- Reifenberger J, "Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas", Int J Cancer, 109, pp.377~384 (2004)
- Trovisco V, "A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma", Hum Pathol, 36, pp.694~697 (2005)
- Milbury CA, "PCR-based methods for the enrichment of minority alleles and mutations", Clin Chem, 55, pp.632~640 (2009)